Twice-Yearly HIV Prevention Shot Offers Hope, But High Price Raises Concerns
A groundbreaking HIV prevention injection, Yeztugo (lenacapavir), recently approved by the U.S. Food and Drug Administration, promises to significantly reduce new infections worldwide, including in Southeast Asia. Experts say this long-acting, twice-yearly shot could help overcome challenges associated with daily HIV-prevention pills, potentially transforming the fight against HIV/AIDS. However, questions about accessibility, cost, and implementation remain—issues of particular concern for middle-income countries like Thailand.
For Thais, HIV remains a chronic social and public health issue. Despite major progress in prevention and treatment, approximately 5,000 new HIV infections occur annually, according to the Department of Disease Control and UNAIDS (UNAIDS Thailand). While daily pre-exposure prophylaxis (PrEP) pills—such as Truvada and Descovy—have been available, adherence is often hindered by stigma, cost, and the burden of taking medicine every day. Yeztugo aims to change that with a simple regimen: two oral doses followed by a subcutaneous injection every six months.